Approval for labeling and treatment protocol changes.  The device, as modified, will continue to be marketed under the trade name exablate 2000 and is indicated for ablation of uterine fibroid tissue in pre-or per-menopausal women with symptomatic uterine fibroids who desire a uterine sparing procedure and whose uterine size is less than 24 weeks.  Limited information is available regarding the safety and effectiveness of the exablate as a treatment for women who desire pregnancy.  Patients should have completed child bearing.